<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00900419</url>
  </required_header>
  <id_info>
    <org_study_id>00-1108.cc</org_study_id>
    <secondary_id>SPORE 24</secondary_id>
    <secondary_id>P50CA058187</secondary_id>
    <nct_id>NCT00900419</nct_id>
  </id_info>
  <brief_title>Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers</brief_title>
  <official_title>Biomarkers and Dysplastic Respiratory Epithelium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of sputum and tissue in the laboratory from patients with&#xD;
      dysplasia or cancer may help doctors identify and learn more about biomarkers related to&#xD;
      cancer. It may also help the study of cancer in the future.&#xD;
&#xD;
      PURPOSE: This laboratory study is looking at biomarkers in patients with respiratory tract&#xD;
      dysplasia or lung cancer, head and neck cancer, or aerodigestive tract cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine intermediate biomarkers of premalignant respiratory epithelial lesions, such&#xD;
           as genetic mutations or altered growth factor expression, in patients with dysplasia of&#xD;
           the respiratory epithelium or lung cancer, head and neck cancer, or aerodigestive tract&#xD;
           cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Establish a tissue repository of normal and dysplastic respiratory epithelium from&#xD;
           endobronchial forceps and brush biopsy tissue from these patients and from normal&#xD;
           volunteers.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to presence of extensive and severe dysplasia of&#xD;
      the respiratory epithelium (yes vs no).&#xD;
&#xD;
      Participants undergo sputum cytology, white-light (with or without fluorescence)&#xD;
      bronchoscopy, and endobronchial biopsies. Participants also undergo endobronchial brushings&#xD;
      and bronchial secretion collection and possibly bronchoalveolar lavage. Collected samples are&#xD;
      processed by hematoxylin, eosin, and immunohistochemical staining and analyzed for specific&#xD;
      biomarkers. Unused samples are stored in the tissue bank.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 330 participants will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2002</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Genetic mutations or altered growth factor expression</measure>
    <time_frame>After study has completed</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Establishment of a tissue repository of normal and dysplastic respiratory epithelium</measure>
    <time_frame>After study has closed</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Precancerous Condition</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <description>Laboratory test</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Laboratory Test</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sputum cytology</intervention_name>
    <description>Laboratory Test</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
    <description>Laboratory Test</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Sputum sample, Endobronchial biopsy, bronchial secretions, pulmonary lavage, blood and urine.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        High Risk for Lung Cancer, suspected lung cancer, lung cancer.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Meets any of the following criteria:&#xD;
&#xD;
               -  Diagnosis of extensive and severe dysplasia of the respiratory epithelium&#xD;
&#xD;
                    -  Recruited from the SPORE Tissue Procurement Screening Project or by private&#xD;
                       or academic physicians (for patients with moderate or severe dysplasia)&#xD;
&#xD;
               -  Survived 1 or more aerodigestive system carcinoma for â‰¥ 1 year&#xD;
&#xD;
               -  Completely resected stage I non-small cell cancer&#xD;
&#xD;
               -  Undergoing any of the following procedures:&#xD;
&#xD;
                    -  Routine panendoscopy for patients with head and neck cancer&#xD;
&#xD;
                    -  Resection of a bronchogenic carcinoma&#xD;
&#xD;
                    -  Bronchoscopy for diagnosis or staging of suspected lung cancer&#xD;
&#xD;
                    -  Subsequent bronchoscopy for surveillance or monitoring of response to&#xD;
                       endobronchial treatment in patients with prior high-grade dysplasia or worse&#xD;
&#xD;
                    -  No asthma&#xD;
&#xD;
                    -  No lung disease&#xD;
&#xD;
                    -  No respiratory illness within the past 2 weeks Patients suspected of or at&#xD;
                       risk for neoplastic lung disease who are undergoing a bronchoscopy in which&#xD;
                       differential diagnostic considerations may include multiple other etiologies&#xD;
                       such as infection and other processes.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  No clinically apparent bleeding diathesis&#xD;
&#xD;
          -  No known bleeding disorder&#xD;
&#xD;
          -  No anginal&#xD;
&#xD;
          -  No clinically active coronary artery disease&#xD;
&#xD;
          -  No multifocal premature ventricular contractions&#xD;
&#xD;
          -  No poorly controlled congestive heart failure&#xD;
&#xD;
          -  No myocardial infarction within the past 6 weeks&#xD;
&#xD;
          -  No cardiac dysrhythmia that is potentially life threatening&#xD;
&#xD;
          -  Well-controlled atrial fibrillation or rare (&lt; 2/min) premature ventricular&#xD;
             contractions allowed&#xD;
&#xD;
          -  No ventricular tachycardia or supraventricular tachycardia with a rapid ventricular&#xD;
             response&#xD;
&#xD;
          -  No other serious medical condition that would preclude a patient from undergoing a&#xD;
             bronchoscopy&#xD;
&#xD;
          -  No acute bronchitis or pneumonia within the past 8 weeks except when clinically proven&#xD;
             as a possible result of lung cancer&#xD;
&#xD;
          -  No hypoxemia (i.e., &lt; 90% saturation with supplemental oxygen) before bronchoscopy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>York E. Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brandi Kubala</last_name>
    <phone>303-724-1657</phone>
    <email>brandi.kubala@cuanschutz.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado Cancer Center at UC Health Sciences Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - University of Colorado Cancer Center</last_name>
      <phone>303-724-1657</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>small cell lung cancer</keyword>
  <keyword>squamous lung dysplasia</keyword>
  <keyword>hypopharyngeal cancer</keyword>
  <keyword>laryngeal cancer</keyword>
  <keyword>lip and oral cavity cancer</keyword>
  <keyword>metastatic squamous neck cancer with occult primary</keyword>
  <keyword>nasopharyngeal cancer</keyword>
  <keyword>oropharyngeal cancer</keyword>
  <keyword>paranasal sinus and nasal cavity cancer</keyword>
  <keyword>salivary gland cancer</keyword>
  <keyword>esophageal cancer</keyword>
  <keyword>pulmonary carcinoid tumor</keyword>
  <keyword>tongue cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

